Latest News

TruScreen's CEO Victoria Potarina, speaks to Andrew Scott from Proactive, ahead of the upcoming ASX dual listing and capital raise.

On 11th November 2020, TruScreen CEO, Victoria Potarina, participated in NZX's Retail Investor Webinar - A deep dive into the Kiwi tech industry.

Cervical cancer screening technology company, TruScreen Group Limited (NZX: TRU) advises that it intends to undertake a capital raising initiative, by way of a public…

Cervical cancer technology company TruScreen Group Limited (NZX: TRU) (the Company, TruScreen) announces its preliminary unaudited half-yearly results for the period ended 30 September 2020.…

TruScreen is pleased to provide a copy of its company presentation for Austalia Biotech Invest and Partnering Conference 2020. 

The attached presentation will be delivered at the Annual Meeting of Shareholders 2020.

TruScreen is excited to announce that as of September 2020, we are refreshing our brand identity.

As part of the rationalisation of its distributors network, Truscreen Limited (NZX: TRU) (“the Company”) is pleased to announce that it has appointed prominent medical…

Cervical cancer screening technology company TruScreen Limited (NZX:TRU) (the Company) has released its audited financial results for the year ended 31 March 2020.

Associate Professor Michael J. Campion, TruScreen Medical Advisory Committee member, sits down to discuss the science behind TruScreen's Cervical Cancer Screening Device, it's clinical validation…